BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating a fixed combination of the Company’s Rho kinase (ROCK) inhibitor, AR-12286, with a commercially available prostaglandin, travoprost, for the treatment of glaucoma. Patients treated with the higher of two dose levels of the fixed combination product demonstrated a statistically significantly greater lowering of intraocular pressure (IOP) compared to travoprost monotherapy. Further, patients maintained their low IOP throughout the day with once-daily evening dosing of the AR-12286/travoprost combination. In addition, Aerie’s investigational product was well-tolerated. There were no serious side effects reported in the study; mild to moderate and transient hyperemia (eye redness) was observed in a minority of patients and was consistent with that seen for the individual components alone. Based upon these results, Aerie is advancing the fixed dose combination to a Phase 2b study.
